PCVX · Insider Trading
Vaxcyte, Inc. Common Stock
Every open-market purchase and sale reported by PCVX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Elvia Cowan | SVP, Finance & CAO | MIXED | — | −$104.99K |
| 2026-11-04 | Jim Wassil | EVP, Chief Scientific Ofc, COO | MIXED | — | −$124.99K |
| 2026-10-07 | Jim Wassil | EVP, Chief Scientific Ofc, COO | MIXED | — | −$1.47M |
| 2026-10-07 | Elvia Cowan | SVP, Finance & CAO | MIXED | — | −$1.16M |
| 2026-10-02 | Jim Wassil | EVP, Chief Scientific Ofc, COO | MIXED | — | −$115.48K |
| 2026-09-09 | Elvia Cowan | SVP, Finance & CAO | F | −1,327 | −$80.10K |
| 2026-09-09 | Andrew Guggenhime | PRESIDENT AND CFO | F | −7,155 | −$431.88K |
| 2026-09-09 | Jim Wassil | EVP, Chief Scientific Ofc, COO | MIXED | −8,174 | −$493.37K |
| 2026-09-09 | Luis Jodar | Chief Medical Officer | A | +52,632 | — |
| 2026-09-09 | Grant Pickering | CHIEF EXECUTIVE OFFICER | F | −17,056 | −$1.03M |
| 2026-09-09 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | F | −7,651 | −$461.81K |
| 2026-09-02 | Elvia Cowan | SVP, Finance & CAO | F | −569 | −$34.83K |
| 2026-09-02 | Andrew Guggenhime | PRESIDENT AND CFO | F | −2,705 | −$165.50K |
| 2026-09-02 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | F | −1,020 | −$62.51K |
| 2026-09-02 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | −3,932 | −$365.82K |
| 2026-09-02 | Grant Pickering | CHIEF EXECUTIVE OFFICER | F | −6,289 | −$384.87K |
| 2026-08-05 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | — | −$109.16K |
| 2026-08-05 | Andrew Guggenhime | PRESIDENT AND CFO | MIXED | — | −$485.38K |
| 2026-08-05 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | MIXED | — | −$513.64K |
| 2026-07-28 | Grant Pickering | CHIEF EXECUTIVE OFFICER | MIXED | −2,000 | −$979.49K |
| 2026-07-16 | John Markels | Director | A | +23,029 deriv. | — |
| 2026-07-06 | Andrew Guggenhime | PRESIDENT AND CFO | MIXED | — | −$519.34K |
| 2026-07-06 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | −1,734 | −$123.98K |
| 2026-06-26 | Grant Pickering | CHIEF EXECUTIVE OFFICER | Sell | −24,237 | −$1.34M |
| 2026-06-23 | Moncef Slaoui | Director | A | +26,061 deriv. | — |
| 2026-06-18 | Grant Pickering | CHIEF EXECUTIVE OFFICER | MIXED | −24,236 | −$1.28M |
| 2026-06-18 | Andrew Guggenhime | PRESIDENT AND CFO | MIXED | — | −$476.50K |
| 2026-06-16 | Heath Lukatch | Director | A | +2,265 | — |
| 2026-06-16 | Halley E Gilbert | Director | A | +2,265 | — |
| 2026-06-16 | Jacks Lee | Director | A | +2,265 | — |
| 2026-06-16 | Olivier Brandicourt | Director | A | +2,194 | — |
| 2026-06-16 | Anne S Drapeau | Director | A | +2,265 | — |
| 2026-06-16 | Teri Loxam | Director | A | +2,265 | — |
| 2026-06-16 | John Furey | Director | A | +2,265 | — |
| 2026-06-16 | Carlos V Paya | Director | A | +2,265 | — |
| 2026-06-03 | Jim Wassil | CHIEF OPERATING OFFICER | Sell | −2,250 | −$111.42K |
| 2026-05-01 | Jim Wassil | CHIEF OPERATING OFFICER | Sell | −2,250 | −$127.87K |
| 2026-04-08 | Elvia Cowan | SVP, Finance & CAO | MIXED | — | −$102.24K |
| 2026-04-03 | Jim Wassil | CHIEF OPERATING OFFICER | Sell | −2,250 | −$131.48K |
| 2026-03-18 | Elvia Cowan | SVP, Finance & CAO | Sell | −1,892 | −$105.15K |
| 2026-03-11 | Andrew Guggenhime | PRESIDENT AND CFO | F | −1,021 | −$60.57K |
| 2026-03-11 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | F | −604 | −$35.83K |
| 2026-03-11 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | −8,370 | −$493.28K |
| 2026-03-11 | Elvia Cowan | SVP, Finance & CAO | MIXED | −495 | −$111.05K |
| 2026-03-11 | Grant Pickering | CHIEF EXECUTIVE OFFICER | F | −3,685 | −$218.59K |
| 2026-03-02 | Andrew Guggenhime | PRESIDENT AND CFO | MIXED | +42,957 | −$118.20K |
| 2026-03-02 | Harpreet S. Dhaliwal | Chief Technical Ops Officer | MIXED | +52,652 | −$46.92K |
| 2026-03-02 | Elvia Cowan | SVP, Finance & CAO | MIXED | +17,828 | +$164.73K |
| 2026-03-02 | Grant Pickering | CHIEF EXECUTIVE OFFICER | MIXED | +99,716 | −$334.32K |
| 2026-03-02 | Jim Wassil | CHIEF OPERATING OFFICER | MIXED | +33,340 | +$79.50K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Grant Pickering | CHIEF EXECUTIVE OFFICER | 563,117 | $37.90M |
| Andrew Guggenhime | PRESIDENT AND CFO | 157,166 | $10.58M |
| Jim Wassil | EVP, Chief Scientific Ofc, COO | 145,778 | $9.81M |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | 68,085 | $4.58M |
| Luis Jodar | Chief Medical Officer | 52,632 | $3.54M |
| Mikhail Eydelman | SVP, GEN COUNSEL & CORP SEC | 41,732 | $2.81M |
| Elvia Cowan | SVP, Finance & CAO | 30,860 | $2.08M |
| Heath Lukatch | Director | 19,481 | $1.31M |
| Anne S Drapeau | Director | 12,481 | $840.10K |
| Halley E Gilbert | Director | 12,481 | $840.10K |
| Carlos V Paya | Director | 12,481 | $840.10K |
| Teri Loxam | Director | 12,481 | $840.10K |
| Jacks Lee | Director | 6,856 | $461.48K |
| John Furey | Director | 5,306 | $357.15K |
| Olivier Brandicourt | Director | 4,699 | $316.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PCVX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.